|
|
|
|
Chatham Street Caf To Host Fundraiser For Triangle Walk To Defeat ALS
Downtown Cary Restaurant To Host Wine Tasting Benefit On March 22 [USPRwire, Sun Mar 21 2010] Gayla Bonke, owner and chef at Chatham Street Caf & Catering (www.chathamstreetcafe.com), located at 140 E.Chatham St., has announced that the restaurant will...
|
|
|
Medical News: Cytokinetics Announces Opening Of A Phase IIa "Evidence Of Effect" Clinical Trial Of CK-2017357 For Patients With Amyotrophic Lateral Sclerosis
Cytokinetics, Incorporated (NASDAQ: CYTK) announced that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.CK-2017357 is a fast...
|
|
|
ALS victims still looking for answers
Members of Cookevilles ALS/Lou Gehrigs Disease support group, Power for the Journey, meet to plan for the upcoming walk to raise funds for the research of the disease.Pictured, in front, from left, are Jackie Maxwell, Ann Philson and Joyce Jordan. In back...
|
|
|
Chatham Street Caf To Host Fundraiser For Triangle Walk To Defeat ALS
Downtown Cary Restaurant To Host Wine Tasting Benefit On March 22 [USPRwire, Sun Mar 21 2010] Gayla Bonke, owner and chef at Chatham Street Caf & Catering (www.chathamstreetcafe.com), located at 140 E.Chatham St., has announced that the restaurant will...
|
|
|
Medical News: Trophos Completes Patient Enrolment In Pivotal Phase 3 Efficacy Study Of Olesoxime In Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment with over 500...
|
|
|
Trophos Completes Patient Enrolment In Pivotal Phase 3 Efficacy Study Of Olesoxime In Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment with over 500...
|
|
|
Trophos Completes Patient Enrolment in Pivotal Phase 3 Efficacy Study of Olesoxime in Amyotrophic Lateral Scle
rophos SA announced the completion of patient enrolment with over 500 patients recruited into the pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS).The study is supported by the EU FP7 MitoTarget project.
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral ..
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis Refer to a friend Marketwire 2010 SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/19/10 --...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
OUTH SAN FRANCISCO, CAMARKETWIRE Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
(MARKETWIRE via COMTEX) ----Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
(MARKETWIRE via COMTEX) ----Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA (MARKET WIRE) 03/19/10 Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/19/10 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/19/10 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis ...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
This Phase IIa EOE clinical trial is a double-blind, randomized, placebo-controlled, three-period crossover, pharmacokinetic and pharmacodynamic study of CK-2017357 in male and female patients with ALS.At least 36 and up to 72 patients may be enrolled in...
|
|
|
Cytokinetics Announces Opening of a Phase IIa 'Evidence of Effect' Clinical Trial of CK-2017357 for Patients W
ophic Lateral Sclerosis Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa 'Evidence of Effect' (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as...
|
|
|
Trophos Completes Patient Enrolment in Phase 3 Olesoxime Study in ALS (Lou Gehrig's Disease)
Topline results expected 4th quarter 2011 Marseille, France, March 17, 2010 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and...
|
|
|
Medical News: ALS Therapy Development Institute And Aestus Therapeutics, Inc. Collaborate To Investigate Potential Treatments For ALS
The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's...
|
|
|
Improving Binding Specificity of Pharmacological Chaperones That Target Mutant Superoxide Dismutase-1 Linked to Familial Amyotrophic Lateral Sclerosis Using Computational Methods
Harvard NeuroDiscovery Center, Harvard Medical School, Boston, Massachusetts?Laboratory for Drug Discovery in Neurodegeneration, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts Center for Neurologic Diseases Improving Binding...
Journal of Medicinal Chemistry:
Mar 18 2010 1:29PM
Matching: amyotrophic lateral sclerosis
|
Find similar documents
|
|
|
|
Protein Disulfide Isomerase and the Endoplasmic Reticulum in Amyotrophic Lateral Sclerosis
_ Protein Disulfide Isomerase and the Endoplasmic Reticulum in Amyotrophic Lateral Sclerosis.
|
|
|
ALS Therapy Development Institute and Aestus Therapeutics, Inc. Collaborate to Investigate Potential Treatment
Combination of Core Competencies to Lead to New Compounds being Identified and Screened CAMBRIDGE, Mass., March 17 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced their plans today to test...
|
|
|
ALSTDI Aestus partner
Contact: Robert Goldstein, ALS TDI, +1-617-441-7295, rgoldstein@als.net; or Lisa McCormick, Aestus Therapeutics, +1-609-865-4014, lmccormick@aestustherapeutics.com Combination of Core Competencies to Lead to New Compounds being Identified and Screened CAMBRIDGE...
|
|
|
ALS Therapy Development Institute and Aestus Therapeutics, Inc. Collaborate to Investigate Potential Treatments for ALS
The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's...
|
|
|
ALS Therapy Institute pairs with N.J. biotech
Cambridge-based ALS Therapy Institute has teamed up with a New Jersey biotech to test several small-molecule compounds that have the potential to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS), commonly called Lou Gehrigs...
|
|
|
ALS Therapy Development Institute and Aestus Therapeutics, Inc. Collaborate to Investigate Potential Treatments for ALS
The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's...
Birmingham Business Journal:
Mar 17 2010 1:53PM
Matching: amyotrophic lateral sclerosis
|
Find similar documents
|
|
